Todays Report: Today, Atara Biotherapeutics Inc. (ATRA) Given a $47.00 Price Target by Canaccord Genuity Analysts

Today, Atara Biotherapeutics Inc. (ATRA) Given a $47.00 Price Target by Canaccord Genuity Analysts

Atara Biotherapeutics Inc. (NASDAQ:ATRA) received a $47.00 price objective from Canaccord Genuity in a report released on Sunday. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 137.37% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. Jefferies Group initiated coverage on shares of Atara Biotherapeutics in a research note on Monday, October 24th. They issued a “buy” rating and a $23.00 target price for the company. JMP Securities reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 2nd. Goldman Sachs Group Inc. downgraded shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and lowered their target price for the company from $23.00 to $16.00 in a research note on Thursday, September 15th. Finally, Citigroup Inc. upped their target price on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research note on Friday, August 19th. Three investment analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $25.86.

Atara Biotherapeutics (NASDAQ:ATRA) traded up 1.80% on Friday, reaching $19.80. 93,002 shares of the company’s stock were exchanged. Atara Biotherapeutics has a 12 month low of $12.45 and a 12 month high of $40.80. The firm’s 50-day moving average is $16.70 and its 200-day moving average is $19.67. The firm’s market cap is $571.43 million.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Friday, November 4th. The company reported ($0.88) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.10. On average, equities analysts forecast that Atara Biotherapeutics will post ($3.05) earnings per share for the current year.

In related news, insider Mitchall G. Clark sold 2,995 shares of the firm’s stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $19.53, for a total value of $58,492.35. Following the completion of the transaction, the insider now owns 98,182 shares of the company’s stock, valued at $1,917,494.46. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Isaac E. Ciechanover sold 12,000 shares of the firm’s stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $20.87, for a total transaction of $250,440.00. Following the completion of the transaction, the chief executive officer now directly owns 406,578 shares of the company’s stock, valued at approximately $8,485,282.86. The disclosure for this sale can be found here. 16.10% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATRA. Credit Suisse AG increased its position in Atara Biotherapeutics by 1.8% in the third quarter. Credit Suisse AG now owns 20,935 shares of the company’s stock worth $447,000 after buying an additional 369 shares during the period. Panagora Asset Management Inc. acquired a new position in Atara Biotherapeutics during the third quarter worth $110,000. The Manufacturers Life Insurance Company acquired a new position in Atara Biotherapeutics during the third quarter worth $352,000. Morgan Stanley increased its position in Atara Biotherapeutics by 102.9% in the third quarter. Morgan Stanley now owns 7,672 shares of the company’s stock worth $164,000 after buying an additional 3,891 shares during the period. Finally, Northern Trust Corp increased its position in Atara Biotherapeutics by 4.4% in the third quarter. Northern Trust Corp now owns 251,244 shares of the company’s stock worth $5,374,000 after buying an additional 10,509 shares during the period. 74.45% of the stock is owned by institutional investors and hedge funds.

Atara Biotherapeutics Company Profile

Related posts

Leave a Comment